Related Experiment Video
Updated: Mar 12, 2026
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.5K
Future directions in chimeric antigen receptor T cell therapy.
1aDivision of Oncology, Cancer Immunotherapy Program, The Children's Hospital of Philadelphia bDepartment of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Current Opinion in Pediatrics
|November 15, 2016
Summary
Chimeric antigen receptor (CAR) T cell therapy shows remarkable success against B cell acute lymphoblastic leukemia in children and adults. This immunotherapy approach offers durable remissions and holds transformative potential for cancer treatment.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Oncology
Background:
- Immunotherapy impact has grown exponentially.
- Chimeric antigen receptor (CAR) T cells are a key development.
- This therapy is relevant for pediatric and adult oncology.
Purpose of the Study:
- To review the impact of CAR T cell therapy.
- To highlight its relevance in pediatric and adult clinical trials.
- To discuss recent findings and future potential.
Main Methods:
- Review of clinical trials involving CAR-modified T cells.
- Analysis of antitumor responses and remission rates.
- Exploration of challenges and novel approaches for CAR T cell therapy.
Main Results:
- CAR T cells targeting CD19 show dramatic antitumor responses in B cell acute lymphoblastic leukemia.
- High complete remission rates (61-93%) observed in pediatric and adult trials.
- Durable remissions are achievable with this therapy.
Conclusions:
- CAR T cell therapy has produced unprecedented results.
- Expansion into other indications and frontline therapy is anticipated.
- This approach has transformative potential for long-term disease control.
